The Union Cabinet headed by Prime Minister Narendra Modi, approved the BioE3 policy, which stands for Biotechnology for Economy, Environment and Employment, in August 24, 2024. India’s biotechnological economy grew to reach $195.3 billion in 2025, which represents a growth rate of 18 per cen compared to $165 billion in 2024, with it being valued only at $10 billion back in 2014. The India Bioeconomy report 2026 published by BIRAC during its 14th Foundation Day in March 2026 documented this remarkable growth path that reflects almost 20-fold increase in a decade. This sector is now contributing close to 5 per cent of India’s GDP. The government stated target is $300 billion by 2030 and if the current momentum is any guide that ambition is well within reach.
What exactly is BioE3?
At its core, BioE3 is India’s first comprehensive national policy framework for biotechnology a blueprint that fuses bioscience with engineering, artificial intelligence and digital tools to create a high-performance biomanufacturing ecosystem. It encapsulates its three-pronged mission Economy, Environment and Employment.
Implemented by the Department of Biotechnology(DBT) and BIRAC public sector undertaking BioE3 identifies six strategic thematic areas of national importance. These are bio-based chemicals, biopolymers, active pharmaceutical ingredients(APIs) and enzymes which are smart proteins and functional foods, precision biotherapeutics including cell and gene therapy, climate-resilient agriculture, carbon capture, marine and space research. Each of these verticals is not chosen arbitrarily they map directly onto India’s most pressing developmental and environmental challenges.
The policy draws upon cutting-edge tools such as genome editing, synthetic biology, metabolic engineering, bioprocess engineering and AI/ML platforms to revolutionise how India manufactures bio-based products at scale, sustainably and competitively. As Union Minister of State(Independent Charge) for Science and Technology Dr. Jitendra Singh informed the Rajya Sabha on April 2, 2026, eleven calls for proposals have already been announced across the six thematic areas, covering both discovery and application-oriented research as well as scale-up initiatives.
The Bio-enablers: Building the backbone
The most transformative aspect of BioE3 is its physical infrastructure vision. The policy applies for a nationwide network of state-of-the-art shared facilities under the evocative Sanskrit banner of ‘Mulankur Bio Enablers’ a reference to the first sprouting of a seed, symbolising India’s bio-industrial germination. This network encompasses Bio-Artificial Intelligence(Bio-AI) Hubs, Biofoundries and Biomanufacturing Hubs all are designed in Public-Private Partnership mode.
In September 2025 the first anniversary of the policy, Dr. Jitendra Singh unveiled India’s first National Biofoundry Network a pan-India initiative comprising 21 bio-enabler facilities. These network is designed to tackle a critical bottleneck that has long plagued Indian biotech the cooperation between laboratory proof of concept and commercial scale production. Startups and academic institutions have struggled with the enormous capital expenditure required to build independent pilot facilities. BioE3 addresses this head-on by providing shared access to these resources by lowering the barrier to scale-up.
The newly inaugurated DBT-ICGEB Bio foundry in New Delhi exemplifies this vision in action. The facility bridges laboratory innovation and industrial scale biomanufacturing by deploying the Design-Build-Test-Learn (DBTL) cycle which replaces slow, manual processes with bio-automation and using artificial intelligence. It uses microbial platforms such as bacteria and yeast, with the ability to scale production to 20 litres, enabling rigorous validation of bio-based solutions before handoff to industry partners. Specialised training workshops includes the ‘Bench to Bioautomation’ programme held in March 2026 equipping the next generation of scientists to master these automated cycles.
From Space to Soil: Range of BioE3 Applications
The BioE3 ambition is genuinely going to make India as Vishwaguru. Under the Marine and Space Research vertical, India has already sent biotechnology experiments to the International Space Station (ISS) itself. Three indigenous microalgal species Chlorella sorokiniana, Parachlorella kessleri and Dysmorphococcus globosus were tested aboard the ISS as part of experiments conducted by Gaganyatri Group Captain Subhanshu Shukla earlier this year. In parallel two cyanobacteria strains an Indian isolate of Spirulina and a fast-growing Synechococcus strain were studied for their growth under microgravity conditions. These organisms carry dual potential capturing excess carbon dioxide inside the ISS cabin while producing vital nutrients for astronauts and growing rapidly on Earth to yield high-value industrial products.
Closer to the ground BioE3 is reshaping agriculture in the Northeast. State BioE3 Cells have been notified by the governments of Assam and Sikkim, making them the first states in the country to operationalise the Centre-State partnership framework under this policy. Projects already underway in the North-Eastern Region include developing microalgae-based carbon capture systems at IIT Guwahati, carbon sequestration through bioengineered plant systems in Meghalaya, and biotechnological interventions to revitalise large cardamom cultivation in Sikkim a crop of enormous cultural and economic significance to the region. 10 per cent of the total budget under the Biomanufacturing and Biofoundry component has been ring fenced for such North-Eastern projects.
Jobs, youths and the innovation in pipeline
The Employment in BioE3 is not an afterthought it is a structural commitment. Once fully operational, BioE3 Centres are projected to support over 250 startups and MSME generate an estimated 10,000 skilled jobs and contribute up to $25 billion towards the $300 billion bioeconomy target. Over 11,855 biotech startups are currently operational in India a 15 per cent increase in 2025 alone with a growing number emerging from Tier-2 and Tier-3 cities, democratising innovation in a manner rarely seen in high-technology sectors.
The BioE3 Challenge for Youth, launched in August 2025, takes the policy for youth-orientation. Open to school students from Classes VI to XII, the programme invites young minds to conceptualise biotechnology solutions using the DESIGN framework for defining real needs, Evidence-first solutions, Sustainability by design, Integration with other technologies, Go-to-market strategies and Net-positive impact. Monthly winners receive Rs 1 lakh along with mentoring and recognition, while 100 selected awardees can access up to Rs 25 lakh in funding through BIRAC to convert their ideas into proof-of-concept realities. These students also gain access to BRIC+ incubation facilities nationwide. It is by any measure, a serious pipeline-building exercise for the bioeconomy of tomorrow.
Viksit Bharat and the circular bioeconomy vision
BioE3 is deliberately woven into India’s larger civilisational ambitions. The policy of BioE3 aligns with the ‘Net Zero’ carbon economy target, the Lifestyle for Environment(LiFE) initiative and the broader vision of Viksit Bharat 2047 for a developed self-reliant India. By prioritising carbon capture and utilisation, bio based alternatives to fossil derived chemicals and climate-resilient agricultural practices, BioE3 positions biotechnology as a central tool in India green transition. The government has also announced a complementary Rs 1 lakh crore Research, Development and Innovation(RDI) Fund and the Rs 10,000 crore Biopharma SHAKTI scheme, aimed at building a globally competitive domestic ecosystem for biologics and biosimilars.
The Bio-RIDE scheme, running alongside BioE3 merges earlier biotechnology R&D and entrepreneurship schemes with a new Biomanufacturing and Bio foundry component, with a proposed financial outlay of Rs 9,197 crore through the 15th Finance Commission period. In a country of India’s scale and complexity, policy ambition must always be matched by fiscal seriousness and on this count, BioE3 and its supporting frameworks appear to be meeting the moment.
India has long been acknowledged as a pharmacy to the world, producing affordable vaccines and generics that have saved millions of lives globally. BioE3 aspires to build on that foundation and construct something far larger a bioeconomy that drives green growth, generates quality employment, secures food and health for 1.4 billion citizens, contributes meaningfully to the planet’s climate goals and in the process, establishes India as the undisputed nerve centre of the global biotech revolution. The seed has been planted. And the first eighteen months is having positive indication.
